RxDoctor Payments Data

Rajan Sood, MD

Internal Medicine · Bowie, MDNPI 1801873898

Payments from drug & device makers

$2,248in general payments, 2019–2025

Across 88 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$905
  • Boston Scientific$538
  • Novo Nordisk$162
  • Sunovion Pharmaceuticals Inc.$122
  • Canon Medical Systems USA, Inc.$96
  • Lundbeck LLC$86
  • plus $338 from 10 others

What the payments were for

  • Food & beverage$2,241100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,248 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$29,974
Medicare patients
117
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan70$46,234
EliquisApixaban75$43,200
JardianceEmpagliflozin59$34,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$30,562
LinzessLinaclotide58$30,364
RexultiBrexpiprazole20$29,607
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,839
Aripiprazole14$645
Quetiapine Fumarate17$352
Olanzapine12$269
Risperidone22$220
Benztropine Mesylate27$191
Trazodone Hcl30$149
Metformin Hcl11$141
Hydroxyzine Pamoate13$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$62$30,36458 claims
Otsuka America Pharmaceutical, Inc.Rexulti$14$29,60720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →